Caplin Steriles Limited, the sterile injectables subsidiary of Chennai-based Caplin Point Laboratories, received a second US Food and Drug Administration approval for a generic antiviral injectable product on Tuesday, extending the momentum generated by its recently cleared foscarnet sodium injection, according to a regulatory filing submitted to Indian stock exchanges.
The new approval, for a product targeting viral infections in immunocompromised patients, comes within days of the company's foscarnet sodium clearance — a drug addressing cytomegalovirus and herpes simplex virus infections with an estimated US market value of approximately $40 million annually. Analysts tracking the Indian generic pharmaceutical sector noted that Caplin Steriles has been executing a targeted strategy of filing for niche, low-competition injectable ANDAs in the US market, where hospital formulary demand remains strong.
Caplin Point's share price rose approximately 3 percent on BSE during morning trading following the announcement, with brokerage notes citing the injectable approval pipeline as a key medium-term earnings driver. The company's Puducherry-based manufacturing facility, which holds US FDA certification, supplies finished sterile dosage forms for the North American market.
"Niche antiviral injectables represent exactly the segment where a mid-tier Indian manufacturer can compete effectively — limited filers, stable hospital demand, and meaningful price realisation," said a Mumbai-based pharmaceutical equity analyst. Caplin Steriles currently has over 60 ANDAs filed with the US FDA across therapeutic categories, with injectables comprising the majority of its US-facing pipeline.
The approval adds to a broader trend of Indian generic manufacturers securing US FDA clearances in speciality injectables as the agency works through its backlog of pending applications. Rivals including Hikma, Fresenius Kabi, and Aurobindo Pharma have similarly targeted hospital-use antivirals and anti-infectives as a growth avenue, making Caplin's latest clearance a competitive signal for the segment.